These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 1020362)
21. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases]. Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128 [TBL] [Abstract][Full Text] [Related]
22. Characteristics and outcome of tuberculosis patients whose sputum smears are positive at or after 5 months of treatment. Harries AD; Gausi F; Chimzizi R; Salaniponi FM Int J Tuberc Lung Dis; 2004 Mar; 8(3):384-7. PubMed ID: 15139479 [TBL] [Abstract][Full Text] [Related]
23. [Preventive chemotherapy in persons with silicosis and silicotuberculosis (author's transl)]. Sturm W; Wattky IM Z Erkr Atmungsorgane; 1976 Apr; 145(1):75-82. PubMed ID: 960785 [TBL] [Abstract][Full Text] [Related]
24. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
25. When are follow-up sputum smears actually examined in patients treated for new smear-positive pulmonary tuberculosis? Harries AD; Gausi F; Salaniponi FM Int J Tuberc Lung Dis; 2004 Apr; 8(4):440-4. PubMed ID: 15141736 [TBL] [Abstract][Full Text] [Related]
26. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis. Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC; Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516 [TBL] [Abstract][Full Text] [Related]
27. Evaluation and planning in national tuberculosis control programmes: the usefulness of the standardised patient treatment card. Ipuge YA; Rieder HL; Becx-Bleumink M; Kimerling ME East Afr Med J; 1997 Dec; 74(12):816-8. PubMed ID: 9557430 [TBL] [Abstract][Full Text] [Related]
28. [Silicotuberculosis and ethambutol treatment]. Kollmeier H; Ilgner M; Voss H; Winkler E Med Klin; 1968 Jun; 63(24):964-7. PubMed ID: 5700946 [No Abstract] [Full Text] [Related]
29. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study]. Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566 [TBL] [Abstract][Full Text] [Related]
30. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion. Sundaram V; Fujiwara PI; Driver CR; Osahan SS; Munsiff SS Int J Tuberc Lung Dis; 2002 Mar; 6(3):238-45. PubMed ID: 11934142 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Prasad R; Verma SK; Sahai S; Kumar S; Jain A Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675 [TBL] [Abstract][Full Text] [Related]
33. [Fully supervised ambulatory short-course chemotherapy with an intermittent regimen for newly diagnosed smear-positive pulmonary tuberculosis]. Xu RX Zhonghua Jie He He Hu Xi Za Zhi; 1987 Oct; 10(5):261-3, 307. PubMed ID: 3131029 [No Abstract] [Full Text] [Related]
34. Frequency of isolated positive sputum cultures among pulmonary tuberculosis patients. Al-Hakeem MM; Chaudhary AR; Aziz S; Al-Aska AK Saudi Med J; 2005 Apr; 26(4):634-40. PubMed ID: 15900375 [TBL] [Abstract][Full Text] [Related]
35. Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Zhao FZ; Levy MH; Wen S Int J Tuberc Lung Dis; 1997 Dec; 1(6):570-2. PubMed ID: 9487456 [TBL] [Abstract][Full Text] [Related]
36. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. Kobashi Y; Mouri K; Yagi S; Obase Y; Miyashita N; Oka M J Infect; 2009 Mar; 58(3):197-204. PubMed ID: 18848730 [TBL] [Abstract][Full Text] [Related]
37. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Escudero E; Peña JM; Alvarez-Sala R; Vázquez JJ; Ortega A Int J Tuberc Lung Dis; 2006 Apr; 10(4):409-14. PubMed ID: 16602405 [TBL] [Abstract][Full Text] [Related]
38. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Giosuè S; Casarini M; Ameglio F; Zangrilli P; Palla M; Altieri AM; Bisetti A Eur Cytokine Netw; 2000 Mar; 11(1):99-104. PubMed ID: 10705306 [TBL] [Abstract][Full Text] [Related]
39. Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran. Tabarsi P; Nooraki A; Mirsaeidi M; Amiri M; Baghaei P; Farnia P; Kazempour M; Heidarnazhad H; Alipanah N; Mansouri D; Masjedi MR Respirology; 2008 Jan; 13(1):108-11. PubMed ID: 18197919 [TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study. Subhash HS; Ashwin I; Jesudason MV; Abharam OC; John G; Cherian AM; Thomas K Indian J Chest Dis Allied Sci; 2003; 45(2):97-103. PubMed ID: 12715931 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]